News

This article will examine the ways to detect fraud and data fabrication within a clinical trial.

With looming workforce loss-now much higher than first anticipated-prompting further cutback plans at EMA, the threat to drug developers, suppliers, and patients is intensifying.

Looking beyond the hype to see how innovations such as data, techniques, and technology can be brought together to improve the lives of patients.

July has seen one very positive development in the faltering attempts by Europe's governments to resolve that challenge of providing patients with innovative medicines without bankrupting health budgets.

CBI Conference Producer, Trevor Sosvielle, recently sat down with Matthew Amsden, CEO of ProofPilot to discuss his early work in HIV prevention trials. Amsden shares how these experiences helped shape ProofPilot and its patient-centric clinical trial approach.

In this interview, Sudip Parikh, SVP and Managing Director of Americas at DIA Global, will discuss the latest industry trends, and how DIA NOW is helping to facilitate information across the clinical trials industry.

James Man considers the practical measures firms can take to embed the patient perspective more directly into their R&D planning.

The question is, how much attention should be paid to historical recruitment figures if the team only reviews the data from one (or two) similar studies?

Updated employee announcements, business news, awards, and recognition in the industry today.

In this interview, Jim Streeter, Global Vice President of Life Sciences Product Strategy at Oracle, will elaborate further on Oracle’s strategy with mHealth in clinical trials.

The British government has at last set out its ambitions for cooperation on medicines post-Brexit.

The potential for innovative gene therapies to treat and even cure a range of serious diseases is prompting FDA to ramp up support for developing and testing new products efficiently and effectively.